Last updated: August 6, 2026
The fixed-dose combination of empagliflozin, linagliptin and metformin hydrochloride is marketed in the United States as Trijardy XR by Boehringer Ingelheim and Eli Lilly. Its commercial position depends primarily on the broader growth of empagliflozin, while linagliptin and metformin improve treatment convenience but do not independently drive premium pricing. Product-level revenue is not publicly disclosed. The relevant financial proxy is Jardiance revenue, because empagliflozin is the principal value-generating component of the portfolio.
Trijardy XR has strong clinical positioning in adults with Type 2 diabetes who need SGLT2 inhibition, DPP-4 inhibition and metformin in one extended-release tablet. Its main commercial constraints are competition from generic metformin combinations, increasingly aggressive SGLT2 pricing, GLP-1 and GIP/GLP-1 therapies, formulary controls and the eventual loss of empagliflozin exclusivity.
What is Trijardy XR and how does the three-drug combination work?
Trijardy XR combines:
| Component |
Drug class |
Primary commercial role |
| Empagliflozin |
SGLT2 inhibitor |
Glycemic control, cardiovascular and heart-failure differentiation |
| Linagliptin |
DPP-4 inhibitor |
Incremental glucose lowering without significant hypoglycemia risk |
| Metformin hydrochloride |
Biguanide |
Low-cost foundational Type 2 diabetes therapy |
The product is indicated as an adjunct to diet and exercise for adults with Type 2 diabetes. It is not indicated for Type 1 diabetes or diabetic ketoacidosis. The extended-release formulation is designed to reduce pill burden for patients already requiring all three agents.[1]
Empagliflozin is the strategic anchor. Its cardiovascular and heart-failure data support use beyond glucose reduction, while linagliptin has a neutral cardiovascular profile and metformin remains the standard first-line foundation for many patients. The combination is therefore strongest in patients who are already appropriate candidates for all three mechanisms.
How large is the market for empagliflozin, linagliptin and metformin?
The addressable market is the global Type 2 diabetes market, but commercial growth is concentrated in the SGLT2 inhibitor segment.
Market structure by therapeutic class
| Segment |
Market direction |
Competitive intensity |
Relevance to Trijardy XR |
| SGLT2 inhibitors |
Expanding through heart failure and chronic kidney disease use |
High |
Primary growth engine |
| DPP-4 inhibitors |
Mature and pressured by GLP-1 therapies |
High |
Supports combination use but limits pricing power |
| Metformin |
Mature, generic and low-priced |
Very high |
Enables broad use but adds limited revenue |
| GLP-1 and GIP/GLP-1 therapies |
Rapid growth |
Very high |
Major substitution risk for intensified diabetes treatment |
| Fixed-dose combinations |
Growing selectively |
Moderate to high |
Improves adherence and prescription retention |
Empagliflozin competes directly with dapagliflozin, canagliflozin and ertugliflozin. Jardiance has benefited from cardiovascular, heart-failure and renal positioning. Farxiga, marketed by AstraZeneca, is the principal branded comparator and has expanded beyond diabetes into heart failure and chronic kidney disease.
Linagliptin competes with sitagliptin, saxagliptin and other DPP-4 inhibitors. DPP-4 products remain relevant for patients who need oral therapy and cannot tolerate, access or afford injectable or more expensive incretin-based products. Their long-term market growth is weaker than that of SGLT2 and GLP-1 therapies.
What is the financial trajectory of the empagliflozin franchise?
Public companies do not report Trijardy XR revenue separately. Lilly reports Jardiance revenue, which includes empagliflozin products and does not isolate the three-drug combination. Boehringer Ingelheim does not provide the same level of publicly available brand-level revenue detail.
Public financial indicators
| Metric |
Financial implication |
| Jardiance revenue |
Best public proxy for empagliflozin commercial performance |
| Trijardy XR revenue |
Not separately reported |
| Glyxambi revenue |
Not separately reported |
| Tradjenta revenue |
Not consistently disclosed as a standalone figure |
| Product-level margins |
Not publicly available |
| Co-commercialization economics |
Shared between Lilly and Boehringer under their alliance structure |
Lilly reported Jardiance revenue of approximately $2.8 billion in 2023, reflecting continued demand for empagliflozin in diabetes and cardiovascular indications.[2] The franchise has expanded from a diabetes product into a broader cardiorenal asset. That expansion increases the value of the active ingredient but does not translate dollar-for-dollar into Trijardy XR sales.
The financial trajectory has four phases:
- Launch phase: Trijardy XR gained adoption among patients requiring three oral therapies.
- Expansion phase: Empagliflozin cardiovascular and heart-failure evidence increased physician familiarity and payer relevance.
- Maturity phase: SGLT2 competition and formulary negotiations constrained net price growth.
- Exclusivity pressure phase: Generic empagliflozin or authorized alternatives could reduce branded combination pricing and weaken the value of the fixed-dose product.
When does empagliflozin lose exclusivity?
The key commercial patent question is not the nominal expiration of one compound patent. It is the combined effect of compound, salt, formulation, method-of-use and pediatric exclusivity rights, plus any litigation settlements.
Empagliflozin was originally protected by compound and related patent rights associated with Boehringer Ingelheim and Eli Lilly. The Orange Book contains product-specific listings for Jardiance and related empagliflozin products. Patent coverage can differ among:
- Jardiance tablets;
- Synjardy tablets;
- Synjardy XR extended-release tablets;
- Glyxambi tablets;
- Trijardy XR extended-release tablets;
- cardiovascular and renal methods of use;
- manufacturing and crystalline-form claims.
The practical exposure window is therefore product-specific. A generic company may challenge one listed patent while designing around another, and a settlement may establish a launch date earlier than the latest nominal patent expiry.
Expected exclusivity dynamics
Empagliflozin is likely to face meaningful U.S. generic risk in the late 2020s to early 2030s, depending on the patent challenged, litigation outcome and settlement terms. The exact first-launch date cannot be inferred from the active-ingredient patent alone.
The relevant regulatory milestones are:
| Milestone |
Status |
| Jardiance FDA approval |
2014 |
| Glyxambi FDA approval |
2015 |
| Synjardy FDA approval |
2015 |
| Trijardy XR FDA approval |
2020 |
| New cardiovascular and renal indications |
Expanded after initial diabetes approval |
| Generic risk |
Dependent on Orange Book patents and Paragraph IV litigation |
What patents protect Trijardy XR?
Trijardy XR is protected through a layered estate rather than one standalone patent category.
Active-ingredient patents
Empagliflozin compound and related chemical patents provide the core protection for the SGLT2 component. Linagliptin compound patents provide the core protection for the DPP-4 component. Metformin hydrochloride is generic and contributes little meaningful composition-of-matter protection.
Formulation patents
The principal technical value of Trijardy XR lies in the extended-release, multi-layer or multi-component tablet architecture. Formulation claims may cover:
- controlled release of metformin;
- immediate or modified release of empagliflozin and linagliptin;
- tablet-layer arrangement;
- dissolution profiles;
- excipient combinations;
- stability and manufacturing processes.
Formulation patents can delay direct substitution even after one active ingredient becomes generic. Their strength depends on claim scope, written-description support, enablement, prior art and whether a generic product can use a different release design.
Method-of-use patents
Method-of-use coverage may relate to:
- glycemic control in Type 2 diabetes;
- reduction of cardiovascular death;
- heart-failure hospitalization risk;
- chronic kidney disease outcomes;
- treatment of patient subgroups with cardiovascular or renal disease.
Method patents are commercially important for branded prescribing but are more difficult to enforce against generic substitution because physicians and pharmacies may use a product for multiple indications.
What is the Orange Book status of Trijardy XR?
The FDA Orange Book is the controlling U.S. source for listed patents and regulatory exclusivity for approved small-molecule products. Trijardy XR is an NDA product, not a biologic, so biosimilar rules do not apply. Generic applicants would generally use an abbreviated new drug application and may certify against listed patents under Paragraph IV.
An ANDA applicant can:
- certify that no relevant patent is listed;
- certify that a patent has expired;
- state that the applicant will wait until patent expiration;
- submit a Paragraph IV certification alleging that a listed patent is invalid, unenforceable or not infringed.
A Paragraph IV notice can trigger patent litigation. A timely lawsuit by the patent holder may create an automatic FDA approval stay of up to 30 months, subject to statutory exceptions and court developments.[3]
Because Trijardy XR combines three active ingredients, an ANDA applicant must address both the active-ingredient rights and the specific extended-release combination design. The product could therefore experience a staggered generic pathway rather than an immediate one-for-one substitution.
Which companies are challenging the empagliflozin franchise?
The primary competitive threats are commercial and regulatory rather than limited to known litigation.
Branded competitors
| Company |
Product |
Competitive position |
| AstraZeneca |
Farxiga |
Direct SGLT2 competitor with cardiovascular, heart-failure and renal positioning |
| Johnson & Johnson / Mitsubishi Tanabe |
Invokana |
Earlier SGLT2 entrant with reduced relative momentum |
| Merck |
Januvia |
Major DPP-4 competitor to linagliptin |
| Novo Nordisk |
Ozempic, Rybelsus and related products |
Strong incretin-based substitution threat |
| Eli Lilly |
Mounjaro and Trulicity |
Competes for intensified Type 2 diabetes treatment |
The most important competitive shift is the move from glucose-centric prescribing toward cardiorenal risk reduction and weight management. Empagliflozin benefits from its cardiorenal profile, but GLP-1 and GIP/GLP-1 products compete for the same patients when weight loss, high HbA1c reduction or cardiovascular risk management is prioritized.
Generic competitors
Generic risk may emerge first for individual empagliflozin or linagliptin products rather than for the exact Trijardy XR combination. Once low-cost versions of the underlying ingredients become available, payers may prefer separate tablets over the branded fixed-dose combination.
That creates a substitution pathway:
- generic metformin remains the baseline;
- generic empagliflozin reduces the cost of SGLT2 therapy;
- generic linagliptin or another DPP-4 inhibitor reduces DPP-4 costs;
- separate-tablet regimens compete with Trijardy XR;
- branded combination pricing becomes harder to defend.
How strong is the patent estate for Trijardy XR?
The estate is commercially meaningful but structurally mixed.
| Protection layer |
Relative strength |
Commercial effect |
| Empagliflozin composition patents |
High while enforceable |
Protects the principal value driver |
| Linagliptin composition patents |
High while enforceable |
Supports branded combination economics |
| Metformin composition protection |
Low |
Generic ingredient |
| Extended-release formulation patents |
Moderate to high |
Can delay direct substitution |
| Method-of-use patents |
Moderate |
Supports differentiation but is harder to enforce |
| Manufacturing patents |
Variable |
May raise technical barriers without blocking all competitors |
The estate is strongest before compound-patent expiry and weaker afterward. Formulation patents can preserve a commercial niche, but they rarely sustain the same revenue level as a valid composition-of-matter patent covering the main active ingredient.
What generic launch scenarios exist?
Scenario 1: Delayed direct substitution
A generic company challenges listed patents but cannot launch until the last relevant patent expires or litigation ends. Trijardy XR maintains pricing, although payer pressure increases before launch.
Scenario 2: At-risk launch
A generic launches before final resolution after an unsuccessful or incomplete patent challenge. This can produce rapid price erosion and damages exposure if the patent holder later prevails.
Scenario 3: Authorized generic or settlement launch
The patent holder licenses or authorizes a generic manufacturer to launch on an agreed date. Price erosion begins earlier than an unchallenged expiry but may be controlled through supply and distribution terms.
Scenario 4: Separate-component substitution
Generic empagliflozin and generic linagliptin become available while no exact Trijardy XR equivalent launches immediately. Pharmacists and payers use separate tablets, reducing fixed-dose combination volume.
The fourth scenario is commercially plausible because a generic applicant may prioritize high-volume single-agent products before pursuing a technically complex triple combination.
Does Trijardy XR face biosimilar risk?
No. Trijardy XR contains chemically synthesized small-molecule drugs. The relevant pathway is generic substitution under the ANDA framework, not biosimilar approval under the Public Health Service Act.
The product can still face biological-product competition indirectly. GLP-1 and GIP/GLP-1 therapies are not biosimilar competitors to Trijardy XR, but they compete for the same diabetes treatment budget and prescribing decisions.
What licensing deals affect empagliflozin and linagliptin?
The empagliflozin and linagliptin businesses are tied to the Boehringer Ingelheim-Eli Lilly diabetes alliance. The companies jointly commercialize products including Jardiance, Tradjenta, Glyxambi, Synjardy and Trijardy XR in major markets.[4]
The alliance affects:
- global commercialization;
- regulatory strategy;
- clinical-trial funding;
- sales-force economics;
- product-line expansion;
- patent enforcement;
- revenue sharing.
The alliance also complicates financial analysis because revenue is split across two companies and combination-product sales are not presented as a single transparent public line item.
What regulatory factors will determine future sales?
The strongest regulatory asset is empagliflozin’s expansion into cardiovascular, heart-failure and kidney disease populations. These indications enlarge the market beyond patients requiring additional glucose lowering.
Key regulatory risks include:
- renal-function restrictions and labeling requirements;
- ketoacidosis warnings;
- genital and urinary tract infection risks;
- dehydration and volume depletion;
- perioperative treatment interruption;
- contraindications or limitations related to metformin and renal impairment;
- reduced clinical suitability as kidney function declines.
For Trijardy XR specifically, the combination may be less attractive when a prescriber wants to adjust one component independently. A three-drug tablet improves adherence but reduces dose flexibility.
How does Trijardy XR compare with competing diabetes combinations?
| Product or strategy |
Main advantage |
Main limitation |
| Trijardy XR |
One tablet with SGLT2, DPP-4 and metformin |
High branded cost and limited dose flexibility |
| Synjardy XR |
Empagliflozin plus metformin |
Requires separate DPP-4 or other therapy when needed |
| Glyxambi |
Empagliflozin plus linagliptin |
Does not include metformin |
| Separate generic tablets |
Lowest potential cost |
Higher pill burden |
| SGLT2 plus GLP-1 therapy |
Stronger weight and metabolic profile in many patients |
Higher cost, injection burden for some products |
| DPP-4 plus metformin |
Familiar oral regimen |
Weaker cardiorenal and weight-loss differentiation |
Trijardy XR is most defensible when adherence, pill burden and continued use of all three agents matter. It is less defensible when payers prioritize lowest net cost or when the patient needs flexible titration.
What revenue exposure exists at risk of patent expiry?
The exposure is concentrated in the broader Jardiance franchise rather than Trijardy XR alone. Jardiance has become one of the most valuable products in Lilly’s portfolio, while Trijardy XR is a supporting formulation with smaller undisclosed sales.
A practical exposure framework is:
| Revenue source |
Exposure to empagliflozin patent expiry |
| Jardiance monotherapy |
Very high |
| Synjardy and Synjardy XR |
High |
| Glyxambi |
High |
| Trijardy XR |
High, with added formulation complexity |
| Linagliptin-only products |
Separate, potentially earlier or later exposure |
| Metformin component |
Already generic |
The financial decline after generic entry is likely to be gradual for the overall empagliflozin franchise if cardiorenal indications remain branded and clinically differentiated. Trijardy XR could decline faster because payers can separate its ingredients and use lower-cost alternatives.
Key Takeaways
- Trijardy XR is the fixed-dose combination of empagliflozin, linagliptin and metformin hydrochloride.
- Empagliflozin is the principal commercial and strategic value driver.
- Product-level Trijardy XR revenue is not publicly disclosed; Jardiance revenue is the main financial proxy.
- SGLT2 growth is supported by heart-failure and chronic-kidney-disease use, while DPP-4 growth is mature.
- GLP-1 and GIP/GLP-1 therapies are the largest branded substitution threat.
- Generic risk depends on compound, formulation, method-of-use and Orange Book patent coverage.
- Trijardy XR has no biosimilar exposure because it is a small-molecule product.
- Separate generic tablets may erode Trijardy XR sales before an exact triple-combination generic reaches the market.
- The Boehringer Ingelheim-Eli Lilly alliance controls the principal commercial and licensing framework.
- The product’s patent strength is highest while empagliflozin and linagliptin composition patents remain enforceable.
FAQs
Is Trijardy XR the same as Jardiance?
No. Jardiance contains empagliflozin alone. Trijardy XR contains empagliflozin, linagliptin and extended-release metformin hydrochloride.
Does metformin add meaningful patent value to Trijardy XR?
No. Metformin hydrochloride is a mature generic ingredient. Its commercial role is therapeutic and formulation-related, not composition-of-matter protection.
Can a generic company substitute separate tablets for Trijardy XR?
Yes. Depending on payer and pharmacy rules, generic or lower-cost empagliflozin, linagliptin and metformin products may be prescribed separately, although they are not automatically identical substitutes for the fixed-dose extended-release tablet.
Which product is the closest branded competitor to Trijardy XR?
There is no exact branded equivalent with the same three ingredients. Synjardy XR is the closest empagliflozin-metformin comparator, while Glyxambi is the closest empagliflozin-linagliptin comparator.
Will GLP-1 drugs eliminate demand for Trijardy XR?
No. GLP-1 therapies will pressure demand among patients needing major weight reduction or stronger glucose lowering, but Trijardy XR remains relevant for patients who prefer oral treatment, need cardiorenal therapy and are stable on all three components.
References
- U.S. Food and Drug Administration. (2020). Trijardy XR prescribing information.
- Eli Lilly and Company. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Eli Lilly and Company. (2024). Jardiance and diabetes alliance product information.
- Boehringer Ingelheim. (2024). Jardiance and diabetes medicines corporate product information.
- U.S. Food and Drug Administration. (2024). ANDA approval process and Paragraph IV patent certification guidance.
